Dec 12 2024 20 mins
Visit https://www.peervoice.com/YVF860 to view the entire programme with slides. After completing “Erika Hamilton, MD - Safety First: Recognising and Responding to Toxicities Associated With TROP2-Directed Therapies in Metastatic Breast Cancer”, participants will be able to: Identify common adverse events associated with the use of TROP2-directed agents in the management of advanced breast cancer; and Implement evidence-based best practices in the monitoring, identification, and management of adverse events in patients with advanced breast cancer receiving TROP2-directed therapy.